Jillian Angelo Caccamo

To the Editor: We are writing to express our serious concerns regarding the recent publication of the so-called “new multisociety guidance” on the perioperative management of glucagon-like peptide-1 receptor agonists (GLP-1s) (January/February 2025, page 1). While presented as an authoritative directive, this guidance1 lacks clarity, scientific transparency and practical applicability in real-world surgical settings.

by Ramin Roohipour, MD; Jillian Angelo Caccamo, MS, MD; and Qemal Shaholli Dr. Roohipour is Chief Executive Officer and Medical Director, R&R Surgical Institute in Torrance, California. Dr. Angelo Caccamo is with R&R Surgical Institute in Torrance, California. Mr. Shaholi is Chief Operating Officer, R&R Surgical Institute in Torrance, California. Funding: No funding was provided. Disclosures: The authors report no conflicts of interest relevant to the content of this article. Bariatric Times.